SCHEMBL2118633

SCHEMBL2118633

Cc1ccc(S(=O)(=O)N(C)c2ccc(C)c(-c3ccc([N+](=O)[O-])o3)c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
MCOLN3 Q8TDD5 2/20 0.49
HTT P42858 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TLR9 Q9NR96 1/20 0.45
SLC2A1 P11166 1/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
ALDH1A1 P00352 2/20 0.41
LMNA P02545 3/20 0.41
POLB P06746 1/20 0.41
NPC1 O15118 2/20 0.40
TP53 P04637 1/20 0.40
C5AR1 P21730 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
PTPRC P08575 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117714 0.84 MAPT (0.55) MAPTMCOLN3HTTNPSR1L3MBTL1
SCHEMBL2117308 0.77 MAPT (0.55) MAPTMCOLN3HTTNPSR1L3MBTL1
SCHEMBL6828525 0.76 MAPT (0.61) MAPTMCOLN3HTTNPSR1L3MBTL1
SCHEMBL2121778 0.74 MAPT (0.51) MAPTMCOLN3HTTNPSR1L3MBTL1
SCHEMBL2120185 0.74 MAPT (0.54) MAPTMCOLN3HTTNPSR1L3MBTL1
SCHEMBL2118537 0.72 MAPT (0.55) MAPTMCOLN3HTTNPSR1L3MBTL1
SCHEMBL2119577 0.71 MAPT (0.54) MAPTMCOLN3HTTNPSR1L3MBTL1
SCHEMBL2118443 0.71 LMNA (0.38) MAPTMCOLN3NPSR1TLR9ALDH1A1
SCHEMBL2119840 0.71 PSEN1 (0.42) MAPTMCOLN3HTTNPSR1TLR9
SCHEMBL2120314 0.70 MAPT (0.55) MAPTMCOLN3HTTNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 MAPT 4523/4885MCOLN3 4803/4885HTT 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.